| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -1,654 | -1,365 | -1,398 | -2,684 |
| Amortization of intangible asset | 40 | 40 | 40 | 80 |
| Debt discount amortization | NaN | 0 | 0 | 0 |
| Fair value of common shares issued in connection with the conversion of accounts payable | NaN | 0 | 0 | NaN |
| Fair value of warrants issued in connection with convertible notes payable | NaN | 0 | 0 | NaN |
| Gain on settlement of accounts payable | NaN | 0 | NaN | NaN |
| Vendor advances | NaN | 0 | 0 | NaN |
| Amortization of vendor advances | 220 | 212 | 660 | 1,298 |
| Fair value of vested restricted stock units | 259 | 259 | 70 | 153 |
| Prepaid expenses and other current assets | 92 | 27 | -64 | 50 |
| Accounts payable and accrued expenses | 191 | -203 | -274 | -316 |
| Net cash used in operating activities | -1,036 | -1,084 | -838 | -1,519 |
| Proceeds from common stock issued for cash in connection with the closing of the initial public offering | NaN | 0 | 0 | NaN |
| Proceeds from notes payable - officers | NaN | 0 | 0 | 0 |
| Proceeds from the equity line of credit | NaN | 0 | 3,379 | 223 |
| Proceeds from the sale and exercise of prefunded warrants | NaN | 0 | 0 | 3,058 |
| Proceeds from the at the market (atm) offering | 385 | NaN | NaN | NaN |
| Payment of deferred offering costs | 165 | 0 | 0 | 0 |
| Net increase in cash and cash equivalents | NaN | -1,084 | NaN | NaN |
| Net cash provided by financing activities | 220 | 0 | 3,379 | 3,281 |
| Net increase (decrease) in cash and cash equivalents | -816 | -1,084 | 2,541 | 1,762 |
| Cash and cash equivalents, beginning of period | 4,491 | 5,575 | 1,272 | NaN |
| Cash and cash equivalents, end of period | 3,675 | 4,491 | 5,575 | NaN |
Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD. (KAPA)